3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
13
Prostatic Neoplasms
9
Carcinoma, Hepatocellular
8
Liver Neoplasms
6
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Squamous Intraepithelial Lesions
2
Neoplasms
2
Lymphatic Metastasis
2
Locally Advanced Pancreatic Cancer
2
Kidney Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Carboplatin
71
Docetaxel
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
Electroporation
×
Clear all
NCT02430701
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled